Skip to main content

Originally published June 25, 2013 at 10:49 AM | Page modified June 26, 2013 at 6:29 AM

  • Share:
  • Comments (0)
  • Print

Seattle Genetics signs development deal with Bayer

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >


Seattle Genetics has a new agreement with Bayer HealthCare to jointly develop cancer-fighting drugs.

Bayer will pay fees of up to $20 million for worldwide rights to utilize Seattle Genetics’ auristatin-based antibody-drug conjugates technology.

Antibody-drug conjugates are designed to attack cancer tumor cells in a much more targeted way with the goal of lessening negative effects on healthy cells.

Bothell-based Seattle Genetics could also get up to about $500 million in potential milestone payments, along with royalties on worldwide net sales of any resulting products under the collaboration. Bayer is responsible for research, product development, manufacturing and commercialization of all products under the agreement.

Shares of Seattle Genetics fell 20 cents, or 0.7 percent, to $29.70 at Tuesday’s close.

News where, when and how you want it

Email Icon

 Subscribe today!

Subscribe today!

99¢ for four weeks of unlimited digital access.



The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited content access is included with most subscriptions.

Subscriber login ►